GW Pharmaceuticals Enjoys 10-percent Boost

Technical420.com reported that GW Pharmaceuticals plc (LSE:GWP,NYSE:GWPH) was up over 10 percent on Friday and has risen 36 percent since the start of 2015. The news outlet provided a profile of the company to shed some light on why it’s doing so well.

The company in brief:

Many people think that GW Pharmaceutical is a marijuana company, but they are not. GWPH is a pharmaceutical company focused on developing treatments derived from cannabis. The company has an extensive product pipeline with each product in various stages of FDA testing. The company’s two main products in focus are Sativex and Epidolex.

Their Sativex product for cancer pain is in late stage 3 testing and they expect to receive data in the near future. If the drug is approved by the FDA, GWPH will enter a high demand market where they have no competition.

Epidolex is also a major needle move for GWPH. These treatments offer nearly 250,000 people in the United States and Europe an alternative treatment for intractable epilepsy. Current treatments on the market today are known to have horrible side effects. The latest trials have shown that Epidiolex does not cause any side effects aside of fatigue, which will allow GWPH to dominate the market.

2015 plans:

GW Pharmaceutical sells their Sativex product throughout Europe, but the company has its sights set on entering the United States market during 2015.

The FDA granted the fast track designation to GWPH‘s investigational cannabidiol product, Epidiolex, for the treatment of Dravet syndrome. GWPH expects to complete most of the Epidiolex development program during 2015, as well as start to build a U.S. commercial presence in anticipation of the future launch.

GWPH is progressing towards the conclusion of U.S. Phase 3 cancer pain trials for Sativex, the world’s first plant-derived cannabinoid prescription drug. GWPH expects to report data from the trials in early 2015 which, if positive, would enable the filing of New Drug Application (NDA) with the FDA in the second half of 2015.

Click here to read the full Technical420.com report.